Guidelines on antimicrobial chemotherapy for prevention and treatment of infections in the intensive care unit

Journal of Chemotherapy

Volumn 13, Issue SPEC. ISS. 1, 2001, Pages 134-149

  Bergogne Berezin E ^a  

^a NONE   (France)

Author keywords

Combination therapy; Empiric therapy; Monotherapy; Multiresistant organisms; Nosocomial infection; Surgical infection; Surgical prophylaxis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZTREONAM; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; FOSFOMYCIN; FUSIDIC ACID; IMIPENEM; MACROLIDE; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TICARCILLIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; CHEMOTHERAPY; CONFERENCE PAPER; DISEASE SEVERITY; HOSPITAL INFECTION; HUMAN; INFECTION; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE UNIT; OUTCOMES RESEARCH; PRACTICE GUIDELINE; RISK FACTOR; SURGICAL INFECTION;

EID: 0035722794     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2001.13.supplement-2.134     Document Type: Conference Paper

References (87)

1. Incidence and nature of endemic and epidemic nosocomial infections
2. Epidemiology of nosocomial infections
3. Changing epidemiology of nosocomial infections in human immunodeficiency virus-infected-patients
4. Predominant pathogens in hospital infections
5. th Decennial International Conference on Nosocomial and Healthcare-Associated Infections
6. The changing epidemiology of bacteremia in neutropenic children with cancer
7. The changing epidemiology of severe infections in the ICU
8. The prevalence of nosocomial infection in intensive care units in Europe
9. Predominant pathogens found in the European Prevalence of Infection in Intensive Care study
10. Nosocomial outbreak of Candida albicans sternal wound infection following cardiac surgery
11. National Nosocomial Infections (NNIS) report, data summary from October 1986, April 1996
12. Multiply drug resistant pathogens: Epidemiology and control
13. Resistance not mediated by β-lactamase (methicillin-resistance)
14. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains
15. Coryneform bacteria in infectious diseases: Clinical and laboratory aspects
16. Clinical microbiology of coryneform bacteria
17. In vivo susceptibility of Rhoclococcus equi to 27 antibiotics
18. Risk factors for acquisition of multiply-drug-resistant Gram-negative bacteria
19. Hospital infection with Acinetobacter spp.: An increasing problem
20. Stenotrophomonas (Xanthomonas) maltophilia: A mutidrug resistant nosocomial pathogen
21. Susceptibility of Stenotrophomonas maltophilia to three β-lactams and five βlactam-β-lactamase inhibitor combinations
22. The emergence of epidemic, multiple-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia
23. An overview of nosocomial infections including the role of the microbiology laboratory
24. Vancomycin resistant enterococci
25. The new threats of Gram-positive pathogens: Reemergence of things past
26. Vancomycin resistant enterococcal bacteremia: Natural history and attributable mortality
27. Enterococcus faecium and Enterococcus faecalis bacteremia: Acquisition and outcome
28. Le point sur la résistance aux antibiotiques des staphylocoques
29. Vancomycin resistance in staphylococci
30. Bacteremia and severe sepsis in adults. A multicenter prospective survey in ICUs and wards of 24 hospitals
31. Nosocomial bloodstream infections
32. Surgical infections including burns
33. th Decennial international conference on nosocomial and healthcare-associated infections: A challenge for change
34. Pneumopathies nosocomiales: Étiologies microbiennes et impact thérapeutique
35. Pseudomonas pneumonia in the immuno-compromised patient
36. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients
37. The inanimate environment
38. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
39. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections
40. The intensive care unit
41. Problèmes thérapeutiques liés aux infections bactériennes chez les patients infectés par le virus de l'immunidéficience humaine (VIH)
42. Antimicrobial resistance with focus on beta-lactam resistance in Gram-negative bacilli
43. Principles of tissue penetration of antibiotics
44. Apport de la pharmacologie à l'optimisation d'une antibiothérapie
45. Continuous infusion ceftazidime in intensive care: A randomized controlled trial
46. Antimicrobial action and pharmacokinetics/pharmacodynamics: The use of AUIC to improve efficacy and avoid resistance
47. Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units
48. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy and preventive strategies. A consensus statement
49. Guidelines of infectious diseases society of America
50. The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards
51. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance
52. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia
53. Empiric therapy of bacterial infections in severe neutropenia
54. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
55. Cefepimeamikacin vs ceftazidime-amikacin as empiric therapy for febrile episodes in neutropenic patients: A comparative study
56. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
57. Continuous infusion of vancomycin for severe methicillin-resistant staphylococcal infections
58. Aspiration pneumonia, lung abscess, and empyema
59. Consensus paper on the surveillance of surgical wound infections
60. Guidelines for clinical care: Antiinfective agents for intra-abdominal infections. Recommendations of the Surgical Infection Society
61. Recommandations pour la pratique de l'antibioprophylaxie en chirurgie
62. Definition of sepsis and organ failure guidelines for the use of innovative therapies in sepsis
63. Microbiology: The role of the clinical laboratory
64. Environmental issues and nosocomial infections
65. Susceptibility of bacterial isolates to β-lactam antibiotics from US clinical trials over a 5year period
66. Surveillance of the current resistance of nosocomial pathogens to antibacterials
67. Analysis of risk factors for nosocomial sepsis in surgical patients
68. Gram negative bacteremia: Etiology and ecology
69. Ceftazidime monotherapy vs ceftriaxone/tobramycin for serious hospital acquired gram-negative infections
70. Combination therapy versus monotherapy for gram-negative bacteraemia: A commentary
71. Monotherapy versus beta-lactam-aminoglycoside combination treatment for Gram-negative bacteremia: A prospective, observational study
72. Addition of rifampicin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: Prospective trial using the zelen protocol
73. Pseudomonas aeruginosa: Actualités sur la résistance aux β-lactamines et implications thérapeutiques
74. Acinetobacter spp as nosocomial pathogens: Microbiological, clinical, and epidemiological features
75. Chromosomal cephalosporinases responsible for multiple resistance to newer β-lactam antibiotics
76. Multivariate analysis of risk factors for infection due to penicillin resistant and multidrug resistant Streptococcus pneumoniae: A multicenter study
77. Antibiotic resistance. Nosocomial gram-positive infection
78. Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci
79. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcis faecium
80. Treatment of Gram-positive nosocomial pneumonia
81. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant or failing prior therapy
82. Characterization of the importance of polysaccharide intercellular adhesion/hemagglutinin of Staphylococcus epidermidis in the pathogenesis of biomaterial-based infection in a mouse foreign body infection model
83. Management of critically ill patients with severe sepsis
84. Study on the efficacy of nosocomial infection control (SENIC Project): Summary of study design
85. The role of professional and regulatory organizations in infection control programs
86. Minimizing the potential for nosocomial pneumonia: Architectural, engineering and environmental considerations for the intensive care unit